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Abstract
Allergic rhinitis (AR) is an atopic disease which affects about 600 million people worldwide and results from a complex interplay
between genetic and environmental factors. However genetic association studies on known candidate genes yielded variable
results. The aim of this study is to identify the genetic variants that influence predisposition towards allergic rhinitis in an ethnic
Chinese population in Singapore using a genome-wide association study (GWAS) approach. A total of 4461 ethnic Chinese
volunteers were recruited in Singapore and classified according to their allergic disease status. The GWAS included a discovery
stage comparing 515 atopic cases (including 456 AR cases) and 486 non-allergic non-rhinitis (NANR) controls. The top SNPs were
then validated in a replication cohort consisting of a separate 2323 atopic cases (including 676 AR cases) and 511 NANR controls.
Two SNPs showed consistent association in both discovery and replication phases; MRPL4 SNP rs8111930 on 19q13.2 (OR=0.69,
Pcombined=4.46610
205)a n dBCAP SNP rs505010 on chromosome 10q24.1 (OR=0.64, Pcombined=1.10610
204). In addition, we
also replicated multiple associations within known candidates regions such as HLA-DQ and NPSR1 locus in the discovery phase.
Our study suggests that MRPL4 and BCAP, key components of the HIF-1a and PI3K/Akt signaling pathways respectively, are two
novel candidate genes for atopy and allergic rhinitis. Further study on these molecules and their signaling pathways would help
in understanding of the pathogenesis of allergic rhinitis and identification of targets for new therapeutic intervention.
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Introduction
Allergic Rhinitis (AR) represents a global health problem affecting
approximately 600 million people in the world population [1,2].
Though not life threateningthe impact ofAR on quality oflife,school
and work performances and productivity is significant [2,3].
Furthermore it has co-morbidities such as asthma, rhinosinusitis,
anosmia, otitis media, nasal polyps and lower airway infection
[1,4,5,6]. Atopy is vital in the development of allergic diseases
through an IgE-mediated mechanism. It is a genetic predisposition
usually starting in childhood or adolescence, when individuals are
sensitized and produce IgE antibodies in response to common
allergens [7,8]. However, the mechanism of inheritance, as to how a
genetic predisposition leads to allergic symptoms, is still unclear.
Many factors have been suggested to play a role in development and
expression of atopic diseases such as higher load of irritants and
a l l e r g e ne x p o s u r e ,c h a n g ei nl i f e s t y l e ,p o l l u t i o n ,d i e tc h a n g e sw i t h
diminished nutritive value and also stress [5,9,10,11]. Thus the
pathogenic mechanism of allergic diseases is very complex and is a
result of complex interaction between genetic and environmental
factors especially in the sensitization phase [1,4]. The strongest risk
factor for the development of allergic symptoms has been a strong
familyhistory of allergic disease irrespectiveof the varying prevalence
andenvironmentalrisk factorsacrosspopulationsand societies[9,12].
Various reports support the genetic basis of atopy and allergic disease
[13,14,15,16,17]. Twin studies provide key evidence for a genetic
effect as there was a greater concordance of allergic manifestations
observed in monozygotic compared to dizygotic twins [18,19,20,21]
and the heritability for atopy is estimated to be ranging between 50–
84%. Many candidate genes have been suggested for atopy and
allergic diseases [7,8,19,22,23,24,25,26,27]. To date, a total of five
genome wide association (GWA) studies performed to identify loci
contributing to the development of asthma and related phenotypes
[28,29,30,31]. However, no GWA study has been performed
specifically for allergic rhinitis. In this study we carried out two-stage
GWAS to identify genetic variants which predispose individuals to
the development of atopy and/or allergic rhinitis in Singapore
C h i n e s et h r o u g hag e n o m ew i d ea s s o c i a t i o ns t u d y .
Results
Discovery phase
The demographics and clinical characteristics of the samples
used in the study have been described in Table 1. In the Stage 1,
1065 samples (551 cases and 514 controls) were genotyped in
551766 SNPs by using Illumina Human 610 Quad genotyping
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(see Methods for more details), population stratification was
assessed by using an approach based on principal-components
analysis (PCA). A total of 25 samples with mixed parentage were
identified and removed, and subsequently, PCA for the remaining
case and control samples was carried out with a further 3 outliers
removed. From the PCA plot, the cases and controls still showed
minimal genetic stratification [32]. After all the SNP and sample
quality control analyses, genotype data for 460183 SNPs in 515
atopy cases and 486 Non-allergic non-rhinitis (NANR) controls
were retained for statistical analysis. A small lGC value of 1.01
indicated little inflation of the GWAS results due to population
stratification.
We then tested for genotype-phenotype association analysis
using the Cochran-Armitage trend test. The analysis revealed
moderate association at multiple loci throughout the genome
(Figure 1A). The quantile-quantile (Q-Q) plot of observed P
values for genome-wide association is shown in Figure S1. There
were no SNPs which met the genome wide significance threshold
(1610
24). However, there were 56 SNPs which showed associa-
tion with atopy at the significance level of 1610
24. We analyzed
the subgroup of Atopic patients with Allergic Rhinitis (AR) clinical
symptomology. Figure 1B and Figure S1 shows the results of
the genome-wide association study for AR. The GWAS analysis
for allergic rhinitis revealed 64 SNPs which had a P of less than
1610
24. A total of 31 SNPs were found to be common for both
the phenotypes and hence a total of 77 unique SNPs were tested
for validation in the replication cohort of 2323 cases and 511
NANR controls, all ethnic Chinese from Singapore (Tables S1
and S2).
Replication Phase and combined analysis
The replication study of atopy identified consistent association
at rs8111930 in MRPL4 (Mitochondrial ribosomal protein L4)
gene (OR=0.78, P=0.029) and rs505010 located in the 59
upstream region of the BCAP (B cell adaptor for phosphatidyli-
nositol 3-kinase) gene (OR=0.74, P=0.06) (Table 2). The Q-Q
plot of the p values of the 77 SNPs does not provide evidence for
excess associations in the validation samples for the atopy
phenotype (Figure S4A). Interestingly, the QQ plot of the 77
SNPs in the validation samples of AR (Figure S4B) does show a
clear deviation from the null, suggesting that there are likely some
true associations within the 77 SNPs. However, none of the
associations for AR reached the genome-wide significance due to
the limited sample size of the study. The joint analysis of the
combined GWAS and validation samples reveal suggestive asso-
ciations at the two SNPs (rs8111930, OR=0.69, Pcombined=
7.92610
25; rs505010, OR=0.64, Pcombined=4.09610
204), how-
ever both of them failed to reach genome-wide significance levels.
Furthermore, the replication study of allergic rhinitis also revealed
consistent association at rs8111930 (OR=0.76, P=0.049) and
rs505010 (OR=0.63, P=0.027) (Table 3). The combined
analysis revealed similar association for the atopy phenotype
(rs8111930, OR=0.54, Pcombined=1.34610
204; rs505010, OR=
0.64, Pcombined=6.616210
205), but the evidence for this asso-
ciation is only suggestive. Furthermore, suggestive associations
were also observed at 2 other SNPs, rs13188584 in CSF1R gene
(OR=1.46, Pcombined=7.56610
205) and rs10493377 in the 59
or 39flanking region of DNAJC6 (OR=1.35, Pcombined=
9.50610
204).
Imputation Analysis
To further investigate the observed associations, we imputed the
genotypes of additional SNPs within the regions surrounding
rs8111930 and rs505010 that were not genotyped by using
IMPUTE (v2.0) and the haplotype information from the HapMap
CHB and CHD samples. Only the imputed genotypes with a
posterior probability score of .0.90 were used for association
analyses. The regional plots for the two regions have been shown
in Figure 2A, 2B, and the imputed SNPs, however, did not reveal
any stronger association than the genotyped SNPs.
Bioinformatics analysis of validated SNPs for putative
TFBS
The SNPs which were validated in the replication population
were analyzed for potential transcription factor binding sites
(TFBS) using TRANSFAC [33] and MATCH [34] and verified
using ALIBABA 2.1 computer program [Available at http://www.
gene-regulation.com/pub/programs/alibaba2/index.html. Accessed
2010 Nov 15]. The results have been summarized in Table S3.
Information about the transcription factors potentially binding to
the validated SNPs has been summarized in Table S4. Bioinfor-
matics analysis predicts that the introduction of the SNP rs505010
(CRT) results in the loss of transcription factor binding sites (TFBS)
for 2 important transcription factors (TF), NFAT (Nuclear factor of
activated T-cells) and PU (Ets-like transcription factor identified in
lymphoid B-cells). Interestingly this polymorphism results in the
introduction of a new TFBS for E2F, which is involved in cell cycle
Table 1. Demographic and clinical characteristics of the samples used in the study.
GWAS Replication
Atopy* AR
$ NANR Controls‘ Atopy* AR
$ NANR Controls‘
Subjects 515 456 486 2323 676 511
Age, mean 21.3 21.4 21.6 19.99 19.92 19.62
Gender
Male 226
(43.8%)
213 137
(28.2%)
1149
(49.5%)
310 (45.86%) 189
(36.9%)
Female 289
(56.2%)
243 349
(71.8%)
1174
(50.5%)
366
(54.14%)
322
(63.1%)
*Atopy is defined by a positive SPT reaction to either one of the dust mite allergens (Dermatophagoides pteronyssinus, Blomia tropicalis).
$Allergic Rhinitis (AR) was classified based on 2 or more major symptoms which include (nasal congestion, rhinorrhea, nasal itching, sneezing) and a positive skin prick
test reaction to one of the allergens tested. (Based on 2008 guidelines set by Allergic Rhinitis Impact on Asthma (ARIA) consortium).
‘NANR controls are individuals classified based on no symptoms and history of allergic disease and a negative skin prick test reaction to ALL of the allergens tested.
doi:10.1371/journal.pone.0019719.t001
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(ARG) results in the loss of TFBS for AREB6 (Atp1a1 regulatory
element binding factor 6) and introduces a new TFBS for CREB2
(cAMP-responsive element binding protein).
Non-synonymous SNPs and the predicted function of the
associated SNPs
We also evaluated the associations of non-synonymous SNPs to
atopy and allergic rhinitis separately, and the SNPs with at P
values,0.01 has been described in Table S6. The Q-Q plot for
these SNPs (Figure S5), however, does not provide strong
evidence for excess associations among these SNPs. The SNPs,
rs273957 (CREB3L2), rs2472553 (CHRNA2), rs897945 (THAP9),
rs625372 (SN), rs1919127 (C2orf16) with P values ,0.001 were
subjected to further evaluation for putative effects on the amino
acid and in turn the protein. Tables S7 and S8 describe the
putative effect of these SNPs using the SIFT algorithm and the
FASTSNP algorithm. The SIFT algorithm describes whether the
change in amino acid could be ‘‘tolerated’’ or may be damaging
for the protein. Similarly FASTSNP uses a SNP prioritization
ranking and gives a risk score for each SNP also considering
conserved regions. Thus the effect of the SNP could be estimated
based on the risk score. But further replication in other population
cohorts and also functional studies are needed to validate if these
SNPs actually have an effect on the disease.
Discussion
This is the first GWAS study for AR. We had carried out the
study in two phases: a discovery phase which consisted of 515
atopic cases including 456 AR cases and 486 NANR controls with
no medical history of allergy and a validation phase of 2323 atopic
cases including 676 AR cases and 511 NANR controls. No
associations were discovered at genome-wide significance; howev-
er we observed suggestive associations at rs8111930, an intronic
SNP on MRPL4 gene on chromosome 19p13.2 and rs505010 a 59
flanking SNP to BCAP gene on chromosome 10q24.1 which
showed consistent association evidence between the discovery and
validation samples.
The 19p13.2 locus (rs8111930) was previously reported to be
associated to inflammatory adhesion process and also influencing
soluble ICAM1 (sICAM1) levels [35] and sICAM1 has been
reported by multiple studies to be a key regulator of nasal allergic
reaction [36]. The SNP rs8111930 is an intronic SNP within
MRPL4 gene that codes for the 39S mitochondrial ribosomal
protein L4 (Figure S2). The protein is believed to play a role in
maintaining the structural integrity of the ribosome and also in
mitochondrial protein translation. Interestingly, transcription of
the MRPL4 gene is shown to be down-regulated in TGF-b
differentiated cells [37]. Since MRPL4 is an important component
of the mitochondrial machinery, its regulation by various
transcription factors might be vital in understanding how this
gene might be involved the allergic inflammation pathway. In silico
analysis of rs8111930 (ARG) results in the loss of TFBS for
AREB6 (Atp1a1 regulatory element binding factor 6) and
introduces a new TFBS for CREB2 (cAMP-responsive element
binding protein). AREB6 is a negative regulator of IL-2 gene
transcription after activation of T-cells and is also suggested to be
involved in tissue-specific gene expression and also in early
development [38,39]. Thus studying the regulation of the MRPL4
gene by its polymorphisms might reveal important clues how they
predispose and/or moderate allergic inflammation.
SNP rs505010 is present in the 59 flanking region of BCAP gene
(Figure S3). BCAP is cytosolic adaptor that bridges the B cell
receptor associated kinases to phosphatidylinositol 3-kinase (PI3K)
pathway by regulating the localization of PI3K [40,41]. It is also
involved in the activation, development, and maturation of B cells
and recent reports have shown their role in activation in natural
killer (NK) cells [42,43]. BCAP is demonstrated to be compli-
mentary in function to CD19 in PI3K activation and suggested to
have an important immunoregulatory role in the survival of
mature B cells via activation of c-Rel [41,44]. BCAP-deficient
mice have a considerably lower number of mature B cells and
whose expansion is compromised on BCR stimulation [41,43].
This impaired function in mice lacking BCAP results in a loss of
function phenotype for B cells [43,45]. In contrast NK cells from
mice deficient for BCAP are considerably more long lived,
resistant to apoptosis and have a more mature phenotype with
increased functional activity and enhanced cytokine production
compared to natural killer cells from normal wild type mice [43].
Mutant mouse models of other signaling molecules such as PLC
gamma 2, Btk, Vav, and p85 alpha subunit of PI3K have also
resulted in reduced B cell development [41,43,46,47]. However
the NK cells of these mutant mice are hypo-responsive, contrary to
the NK cells from BCAP-deficient mice. Hence therapeutic
manipulation of BCAP to expand development and function of
NK cells while promoting B cell apoptosis would help in
developing strategies to treat diseases [43,45]. In silico analysis of
the associated SNP, predicts that the SNP rs505010(CRT) results
in the loss of transcription factor binding sites (TFBS) for 2
important transcription factors (TF), NFAT (Nuclear factor of
activated T-cells) and PU (Ets-like transcription factor identified in
lymphoid B-cells). Nuclear factor of activated T cells (NFAT) is a
T-cell-specific transcription factor which enhances the transcrip-
tional activation of GATA3 by targeting the IL-4 promoter [48].
Recently various studies have also suggested that NFAT inhibitors
Figure 1. Genome wide association of SNPs for (A) Atopy phenotype (B) AR phenotype.
doi:10.1371/journal.pone.0019719.g001
Table 2. Summary of results of SNPs significant in the validation study for Atopy phenotype.
GWAS Replication
GWAS+Replication
(2838 cases vs 997 controls)
CHR SNP Gene
Minor
allele
Major
allele Ptrend OR (L95 – U95) Ptrend OR (L95 – U95) Pcombined OR
19 rs8111930 MRPL4 A G 8.69E-05 0.50 (0.35–0.71) 2.98E-02* 0.78 (0.62–0.98) 4.46E-05 0.69 (0.57–0.82)
10 rs505010 BCAP (59utr) C T 1.19E-04 0.40 (0.25–0.64) 6.09E-02 0.74 (0.55–1.01) 1.10E-04 0.61 (0.48–0.79)
doi:10.1371/journal.pone.0019719.t002
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calcineurin inhibitors which are currently being tested in the clinic
[49]. PU.1 strikingly modulates the levels of TCR expression in
CD4 (+) T cells by regulating the DNA-binding activity of GATA-
3 [50]. PU.1 has been also shown to be a key regulator of
transcription of the cathepsin G gene, which has been associated to
allergic rhinitis previously [51]. Interestingly this polymorphism
results in the introduction of a new TFBS for E2F, which is
involved in cell cycle regulation and also interacts with Rbp107
protein. Thus BCAP gene polymorphisms could be significant in
allergic predisposition and progression.
HIF-1a has been reported to be playing significant roles in
inflammatory responses and its inhibition results in reduced
bronchial hyper responsiveness [52]. The PTEN/PI3K pathway
has been targeted towards treatment for asthma and other allergic
phenotypes [53]. Interestingly in a murine model of allergic airway
diseases, mast cells have shown to regulate the activity of HIF-1a
by a PI3K/Akt signaling pathway [54,55]. They also demonstrat-
ed that increased PI3K activity resulted in higher HIF-1a levels,
which were reduced on treatment with inhibitors of PI3K. These
results suggest that HIF-1a is a one of the downstream targets of
PI3K. However, MRPL4 has been recently identified to be a
downstream target of HIF-1a by functional pathway analysis [56].
Hence the study of polymorphisms in MRPL4, BCAP and other
molecules involved in the HIF-1a and PI3K/Akt signaling
pathways might help understand how they are regulated and in
turn shed light on the pathophysiology of allergic rhinitis and other
atopic phenotypes. Taken together these data suggest that
pathway controlling signaling of HIF-1a would interact with
molecules in the PI3K signaling pathways which might lead to the
development and progression of allergic phenotypes such as atopy
and allergic rhinitis. Hence the study of MRPL4, BCAP other
molecules involved in the HIF-1a and PI3K/Akt signaling
pathways might help understand the pathophysiology of allergic
rhinitis and other atopic phenotypes. Recent research has also
shown promise of therapeutic intervention of the HIF-1a as well
PI3K/Akt signaling pathways for treatment of asthma and other
related allergic conditions [57,58,59].
The study does have its limitations. The first limitation is the
sample size for the GWAS and the replication study. The power
calculation for Minor allele frequencies (MAF) thresholds and
different effect sizes based on Odds Ratio has been summarized in
Table S9. This was calculated using the CaTS power calculator
[http://www.sph.umich.edu/csg/abecasis/CaTS/reference.html.
Accessed 2011 April 6]. There was no SNP which met the
genome-wide significance and none of the replication SNPs met
the Bonferroni correction threshold for multiple testing. Another
limitation is that we only selected 77 SNPs (0.00015% of SNPs
genotyped in the GWAS phase) to attempt for replication.
Through our findings in this study, we suggest that it is unlikely
to have any genetic risk factors with effect sizes of OR.1.8 which
would have been observed otherwise. However it would be
interesting to use the data available to perform meta-analysis or
replication in other population in future studies to evaluate the
significance of our results.
Interestingly, evaluation of SNPs in candidate genes/regions
previously reported in GWAS studies for asthma related traits
revealed a strong overlap between atopy, allergic rhinitis and
asthma as the QQ plots showed a significant deviation from null
(Figure S6). Taking a closer look at the SNPs in Table S5,i ti s
evident that genes such as HLA-DQB1, HLA-DRB1, HLA-DQA2,
NPSR1 and PIP-3E are indeed functionally significant in allergy
and related phenotypes. Hence the overlap among the various
phenotypes is quite justified in light of their role in the central
pathogenesis of the allergic phenotype.
In summary using a cohort of 4461 ethnic Chinese from
Singapore we performed the GWAS for atopy and AR and
suggested 2 novel susceptibility loci for atopy and allergic rhinitis.
Further studies would help to confirm and elucidate the role of
these loci in relation to allergic phenotypes. Some of the
polymorphisms previously identified through GWAS for asthma
and related phenotypes also showed suggestive associations in our
GWAS samples, including the SNPs within previously known
candidate regions such the HLA locus on chromosome 6 and the
NPSR1 locus. Hence these results suggest that genetic susceptibility
to complex diseases such as atopy, allergic rhinitis and allergic
asthma might involve a large number of genetic variations,
ranging between rare alleles with strong effects to intermediate to
common alleles with small to moderate effect sizes [60]. Hence
further studies with bigger samples and also the functional
characterization of these disease associated variants would help
elucidate the complex mechanism underlying the genetic predis-
position of diseases.
Materials and Methods
Ethics Statement
This study has been performed with the approval of the
Institutional Review Board of National University of Singapore
(IRB, Reference - NUS07-023 and NUS10-343) and is also in
compliance with the Helsinki declaration. DNA samples used in
this study were collected from ethnic Chinese participants
following standard protocols of informed consent. The consent
Table 3. Summary of results of SNPs significant in the validation study for AR phenotype.
GWAS Replication
GWAS+Replication
(1132 cases vs 997 controls)
CHRSNP Gene
Minor
allele
Major
allele Ptrend OR (L95 – U95) Ptrend OR (L95 – U95) Pcombined OR
10 rs505010 BCAP (59utr) C T 1.11E-03 0.44 (0.27–0.72) 2.69E-02* 0.63 (0.42–0.95) 1.34E-04 0.55 (0.40–0.74)
19 rs8111930 MRPL4 A G 1.25E-04 0.49 (0.34–0.71) 4.95E-02* 0.76 (0.57–1.0) 7.26E-05 0.64 (0.52–0.80)
5 rs13188584 CSF1R T C 2.29E-04 1.62 (1.25–2.10) 7.77E-02 1.27 (0.97–1.66) 9.95E-05 1.44 (1.20–1.73)
1 rs10493377 DNAJC6 (39utr) A G 1.52E-03 1.54 (1.18–2.01) 9.52E-02 1.22 (0.97–1.55) 7.85E-04 1.35 (1.14–1.62)
Ptrend - P values calculated using Cochran Armitage Trend test;
*P value of association ,0.05 in the replication study;
Pcombined - P values calculated combining results from both the GWAS discovery and validation phase using logistic regression.
doi:10.1371/journal.pone.0019719.t003
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Information Sheet which had information about the study.
Study subjects
A total of 4461 study subjects were recruited from the Singapore
Chinese ethnicity through multiple volunteer recruitments in
Singapore. Study subjects were subsequently classified as atopy
cases, AR cases and non-atopic and non-rhinitis (NANR) healthy
controls according to their disease status as determined by ARIA
document [1,4] based questionnaires. Diagnosing procedure
included interview of medical history using a standardized
questionnaire and skin prick test (SPT) using a panel consisted
Figure 2. Regional plots of association results within two susceptibility loci. Association results of both genotyped (triangles) and imputed
(circles) SNPs in the GWAS samples for the regions of ,1000 kb containing rs505010 and rs8111930. For each plot, the 2log10 P values (y axis) of the
SNPs are presented according to their chromosomal positions (x axis), with a grey horizontal line included to indicate suggestive genome-wide
significance (10–3). The genotyped and imputed SNPs are indicated by red-triangles and green-circles respectively. The top SNP is labeled by rs ID.
doi:10.1371/journal.pone.0019719.g002
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pteronyssinus, Blomia tropicalis, Elaeis guineensis and Curvularia lunata.
A wheal diameter of 3 mm or greater is considered as a positive
SPT response. A positive control with histamine and a negative
control of saline were always used. SPT was performed on the
volunteers only if they have not taken any anti-allergic drugs
especially antihistamines for at least 3 days prior to the test. Atopy
is defined by a positive SPT reaction to either one of the dust mite
allergens. AR is thus diagnosed based on the presence of atopic
status and typical AR symptoms as defined by the ARIA guidelines
[1,4] i.e., two or more AR symptoms (nasal congestion,
rhinorrhea, nasal itching, sneezing) persisting for four or more
days a week during the past year. Conversely, the subjects with
NANR are confirmed with no atopy and no typical AR symptoms.
Subjects who could not be recruited into any of the above
categories were excluded from study.
Genomic DNA was extracted from buccal cells obtained from a
mouthwash of 0.9% saline solution following an in-house standard-
ized protocol. In short, the buccal cells were pelleted and lysed; DNA
was extracted using the phenol-chloroform phase-separation tech-
nique purified by two washes in ethanol, with the DNA pellet
resuspended in reduced Tris-EDTA buffer [61]. Samples were
quantified in triplicate on the Nanodrop (ND-1000). Atopy (n=2849)
is defined by a positive SPT reaction to either one of the dust mite
allergens. AR (n=1142) is thus diagnosed based on the presence of
atopic status and typical AR symptoms as defined by the ARIA 2008
guidelines [1,4] i.e., two or more AR symptoms (nasal congestion,
rhinorrhea, nasal itching, sneezing )p e r s i s t i n gf o rf o u ro rm o r ed a y sa
week and lasting for more than 4 weeks continuously. Conversely, the
subjects with NANR (n=1013) are confirmed with no atopy and no
typical AR symptoms. A total of 599 subjects who could not be
diagnosed into any of the above categories or those whose DNA
samples didn’t pass the QC criteria were excluded from study.
Genotyping
A two-stage design for this study: an initial GWAS screening
(the discovery phase) and a follow-up (the replication phase)
analysis was performed.
(1) Discovery phase
A total of 1065 unrelated samples were genotyped using the
Illumina HumanHap 550 k BeadChip, version 3 (Illumina, San
Diego, California) at the Genome Institute of Singapore,
Genotyping core facility. Genotypes were determined using the
Illumina Genome Studio Module, following recommended
protocol. As a part of quality control, SNPs were excluded if they
showed either a call rate lower than 98% in cases or controls, a
minor allele frequency ,1% in the population or significant
deviation from the Hardy-Weinberg equilibrium (HWE) in the
controls with HWE P value ,10
27. Furthermore, all SNPs on the
X, Y and mitochondrial chromosomes as well as the CNV-related
SNPs and probes were excluded from statistical analysis.
(2) Replication phase
Genotyping of new additional 2834 samples for SNPs selected for
replication were performed using matrix assisted laser desorption/
ionization time of flight mass spectrometry (MALDI-TOF MS) for
the determination of allele specific primer extension products using
Sequenom’s MassARRAY system and iPLEX technology (Seque-
nomInc,SanDiego).Thedesignofoligonucleotideswas carried out
according to the guidelines of Sequenom and performed using
MassARRAY Assay Design software. Multiplex PCR amplification
of amplicons containing SNPs of interest was performed using
Qiagen HotStart Taq Polymerase using 5 ng of genomic DNA.
Primer extension reactions were carried out according to manufac-
turer’s instructions for iPLEX chemistry. Assay data were analyzed
using the Sequenom TYPER software. Clustering of genotype calls
was evaluated to determine that the clustering was sufficient for
inclusion in the statistical analysis. All SNPs were also checked for
Hardy-Weinberg equilibrium (HWE) and SNPs were not analyzed
further if they failed HWE.
Statistical Analysis
All statistical analyses were performed by using R program
version 2.10.1 and PLINK version 1.05. As a part of quality control,
we examined the potential genetic relatedness based on pairwise
identity by state for all the successfully genotyped samples using the
PLINK v1.05 software. For any pair of samples identified as first
degree relatives, the sample with lower SNP call rate was removed.
The remaining samples were subsequently assessed for all
population outlier and stratification using a principal component
analysis (PCA) based approach [62]. The original script from
EIGENSTRAT was modified so as to extract the principal
component analysis and plot them. Firstly, PCA was used to
identify genetic outlier using all samples which were genotyped
successfully and passed the QC as mentioned above along with the
Hapmap samples. The Hapmap reference samples were drawn
from the International Hapmap Project: 57 Yoruba in Ibadan,
Nigeria (YRI), 44 Japanese in Tokyo, Japan (JPT), 45 Han Chinese
in Beijing, China (CHB) and 60 CEPH (Utah residents with
ancestry from northern and western Europe) (CEU). We employed
very stringent criterion for the removal of the genetic outliers. A
total of25 samples were removed withfirstprincipalcomponent less
than 0.001 and fourth principal component greater than 0.1 were
removed from the genome-wide analysis. Second, PCA was used to
assess if population stratification exists in our case and control
samples individually. Two outlier samples (both cases) were
removed and a genomic control of lGC=1.0132 was applied to
the association analysis to account for the minimal population
stratification that existed. We checked MAF of the remaining
samples again and14763 SNPs with MAF ,1% were further
removed. After all the SNP and sample quality control analyses,
genotype data of 460183 SNPs in 515 cases and 486 NANR
controls in Singapore population were used in the GWAS. We
performed genome-wide association analyses of Atopy and AR in a
set of 515 Atopy cases (456 cases with AR) and 486 NANR controls.
We performed genotype-phenotype association analysis using
the Cochran-Armitage trend test with PCA-based correction for
population stratification and calculated odds ratio (OR) per allele.
We used the quantile-quantile (Q-Q) plot to evaluate the overall
significance of the genome-wide association results and the
potential impact of population stratification. The impact of
population stratification was also evaluated by calculating the
genomic control inflation factor (lGC). There was minimal
population stratification reflected by a lGC=1.0132 which was
accounted for while calculating the association results. Similar
analysis for the AR phenotype consisting of 456 AR cases and 486
NANR controls revealed a lGC=1.001. Association analysis for
the SNPs genotyped in the replication phase were carried out
using the PLINK v1.05 software. All p-values from the replication
analysis were reported without correction for multiple testing.
Association analysis of the combined samples from the discovery
phase and replication phase samples was done using the Cochran-
Mantel-Hanezel stratification analysis.
Imputation
Untyped genotypes were imputed in the GWAS samples by
using IMPUTE (v2.0) and the haplotype information from the
GWAS on Atopy and Allergic Rhinitis in Singapore
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SNPs with a call rate ,90%, MAF ,0.01 or significant deviation
from Hardy-Weinberg Equilibrium in the controls (7*10-5) were
removed. The association test was performed using a logistic
regression analysis adjusted for study and population stratification
of GWAS samples as described above. Regional plots were
generated using R to show the 2log10 P values.
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